Sino Biopharmaceutical (OTCMKTS:SBMFF) Sees Large Growth in Short Interest

Sino Biopharmaceutical (OTCMKTS:SBMFF) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 98,069,575 shares, an increase of 35.7% from the February 26th total of 72,283,620 shares. Approximately 0.5% of the company’s stock are sold short. Based on an average trading volume of 462 shares, the short-interest ratio is presently 212,271.8 days.

Sino Biopharmaceutical Stock Performance

Shares of OTCMKTS SBMFF opened at $0.76 on Tuesday. The stock’s 50-day moving average is $0.83 and its two-hundred day moving average is $0.90. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.28 and a current ratio of 1.36. Sino Biopharmaceutical has a 1-year low of $0.45 and a 1-year high of $1.24.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited (OTCMKTS: SBMFF) is a Hong Kong–incorporated investment holding company principally engaged in the pharmaceutical sector. Founded in 2000 and listed on the Hong Kong Stock Exchange in 2006, the company has developed an integrated business model that spans research and development, manufacturing and commercialization of healthcare products. Through its subsidiaries, Sino Biopharmaceutical focuses on enhancing China’s domestic pharmaceutical infrastructure while expanding its footprint across key therapeutic areas.

The company’s product portfolio is organized into three core segments: infusion solutions, small-molecule synthetic pharmaceuticals and innovative biologics.